3 stocks over 100% YTD returns: MRIN, NTLA, XELA

3 min read | July 23, 2021 05:48 AM AEST | By Kiran Murali

Google News:

3 stocks over 100% YTD returns: MRIN, NTLA, XELA — Image source: Phongphan,Shutterstock

Recent News

ASX Gold Mining Outlook on ASX 100 Costs and Cash Flow

Gold Portfolio Role Across ASX 300 Resource Markets

ASX Financials Weighting Across ASX 100 Portfolio Exposure

ASX Bank Earnings Outlook on ASX 100 Amid Margin Pressure

Make Kalkine Media
My Trusted Source

Summary

Marin Software (NASDAQ:MRIN) gained 319 percent year to date.

Intellia Therapeutics (NASDAQ:NTLA) returned 177 percent this year.

Exela Technologies (NASDAQ:XELA) soared 114 percent year to date.

The stock markets in the US have registered a robust performance this year. The S&P 500 index gained 16 percent, Dow Jones rose 15 percent, while the Nasdaq Composite returned 13 percent.

Here, we explore three stocks - Marin Software Incorporated (NASDAQ:MRIN), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Exela Technologies (NASDAQ:XELA) – that returned more than 100 percent year to date.

Marin Software Incorporated (NASDAQ:MRIN)

The San Francisco-based company currently has a market cap of US$106.9 million. The stock gained soared 319 percent this year. Its shares traded in the range of US$1.14 to US$27.26.

Marin Software provides a cloud-based digital marketing platform to advertisers, which helps them manage their spending. The MarinOne platform combines search, social and e-commerce advertising into a single platform.

Marin Software reported revenue of US$6.3 million in its first quarter, up 27 percent year over year. Loss from operations decreased to US$2.4 million, compared with US$4.4 million loss in the first quarter previous year.

Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellia Therapeutics’ market cap totals US$11 billion. Its stock returned 175 percent year to date, and the shares traded in the range of US$16.54 and US$202.73 during the last one year period.

The Massachusetts-based company develops curative therapeutics using CRISPR technology. Intellia Therapeutics, along with Regeneron Pharmaceuticals, recently announced positive preliminary data from an ongoing clinical trial of its experimental transthyretin amyloidosis treatment by genome editing.

Earlier in the month, Intellia Therapeutics raised US$690 million in an underwritten public offering of 4,758,620 shares of its common stock for US$145 per share.

In its first quarter, Intellia Therapeutics reported a net loss of US$46.2 million. Collaboration revenue came in at US$6.4 million, while research and development expense was US$39.3 million.

Exela Technologies (NASDAQ:XELA)

Exela Technologies is currently has a market cap of US$172.84 million. The stock jumped 114 percent this year. Its shares were training in the range of 99 cents to US$7.82 in the last 52 weeks.

The Texas-based Exela Technology is a business process automation company. It provides automation services to industries, including banking, healthcare, insurance and manufacturing.

Recently, Exela Technologies said it is rolling out its robotic process automation platform EON for a large health insurance company.

The company reported net loss more than tripled to US$39.2 million in its first quarter as revenue dropped 17.9 percent to US$300.1 million.

Please note: The above constitutes a preliminary view, and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.

The reference data in this article has been partly sourced from EODHD/Others.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.